StockData
MapLight Therapeutics, Inc. logo

MapLight Therapeutics, Inc. (MPLT) shareholders

MPLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$6.57−0.33 (-4.78%)

Close on Nov 17, 2026Market cap $304.70MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
56.6%
26M of 46M shares
Institutional holders
106
37 new, 10 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
10 buys · 145 sales
Net bought $35.99M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Catalyst4, Inc.
Joint filing with Robert Brown (49.90%), Ekemini Riley (49.90%) and 1 more
27,536,01149.90%13D (active) amendmentAug 14, 2026
Mark Vorsatz
Joint filing with Catalyst4, Inc. (45.10%), Robert Brown (45.10%) and 1 more
19,697,46445.10%13D (active)Oct 28, 2025
Forbion Growth III Management B.V.
Joint filing with Forbion Growth Opportunities Fund III Cooperatief U.A. (7.10%)
3,226,4007.10%13G (passive)Dec 31, 2025
T. Rowe Price Investment Management, Inc.3,137,5587.40%13G (passive) amendmentMar 31, 2026
Nan Fung Group Holdings Limited
Joint filing with NF Investment Holdings Limited (5.50%)
2,915,8745.50%13G (passive)Aug 13, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of MPLTValueChange% of portfolio
Novo Holdings A/S3,686,6227.95%$132.13M–7.67%
Fcpm Iii Services B.V.3,226,4006.96%$115.63M–15.41%
T. Rowe Price Investment Management, Inc.2,781,7286.00%$99.70M−20,2090.07%
Goldman Sachs Group Inc1,948,3124.20%$69.83M−46,5610.01%
Price T Rowe Associates Inc /Md/1,422,9353.07%$51.00M+1,310,2270.01%
BlackRock, Inc.1,025,1342.21%$36.74M−314,5970.00%
Nan Fung Group Holdings Ltd971,2532.09%$34.81M–26.47%
5AM Venture Management, LLC950,0112.05%$34.05M–11.83%
Sanofi912,0411.97%$32.69M–6.12%
State Street Corp852,1501.84%$30.54M+513,0340.00%
FMR LLC823,5561.78%$29.52M+619,0550.00%
Vanguard Capital Management LLC784,1501.69%$28.10M+64,3300.00%
Blue Owl Capital Holdings LP729,9291.57%$26.16M−276,0003.94%
Paradigm Biocapital Advisors LP685,8521.48%$24.58MNew0.46%
Pivotal bioVenture Partners Investment Advisor LLC611,4461.32%$21.91M−17.12%
Velan Capital Investment Management LP492,8931.06%$17.67M–10.76%
Siren, L.L.C.450,0000.97%$16.13M–0.33%
Capital World Investors415,7300.90%$14.90MNew0.00%
Geode Capital Management, LLC402,0510.87%$14.41M−79,1500.00%
Baker Bros. Advisors LP364,7050.79%$13.07M–0.07%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202610626M56.6%37 / 2130 / 104M3M
Q1 20268125M53.5%22 / 2614 / 144M4M
Q4 20257426M55.8%74 / 00 / 026M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

FundShares% of MPLTValue% of fundAs of
T. Rowe Price Small-Cap Stock Fund, Inc.625,0461.35%$22.40M0.24%Jun 30, 2026
T. Rowe Price Small-Cap Value Fund, Inc.605,6011.31%$21.70M0.21%Jun 30, 2026
Vanguard Total Stock Market Index Fund552,2791.19%$19.79M0.00%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF498,4281.07%$17.86M0.17%Jun 30, 2026
Fidelity Stock Selector Small Cap Fund406,4020.88%$5.29M0.07%Jul 31, 2026
SMALLCAP World Fund Inc404,3890.87%$14.49M0.02%Jun 30, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund402,7920.87%$14.44M0.15%Jun 30, 2026
T. Rowe Price New Horizons Fund, Inc.398,8090.86%$14.29M0.10%Jun 30, 2026
T. Rowe Price Institutional Small-Cap Stock Fund342,3430.74%$12.27M0.24%Jun 30, 2026
iShares Russell 2000 ETF267,7700.58%$9.60M0.01%Jun 30, 2026
Fidelity Series Small Cap Opportunities Fund263,5290.57%$3.43M0.07%Jul 31, 2026
Vanguard Extended Market Index Fund216,3120.47%$7.75M0.01%Jun 30, 2026
Fidelity Advisor Biotechnology Fund202,9000.44%$2.64M0.12%Jul 31, 2026
Fidelity Series Small Cap Core Fund138,4000.30%$1.80M0.11%Jul 31, 2026
Vanguard Explorer Fund131,3680.28%$1.71M0.01%Jul 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Christopher A. KroegerChief Executive Officer, Director1,297,0992.80%Oct 16, 2026
Anatol KreitzerChief Discovery Officer168,6780.36%Oct 16, 2026
Jonathan GillisCAO and Interim CFO142,3150.31%Oct 16, 2026
James Woodruff LillieChief Scientific Officer198,5970.43%Oct 16, 2026
Erin Pennock FoffChief Medical Officer296,9060.64%Oct 16, 2026
Kristopher HansonGeneral Counsel128,0240.28%Oct 16, 2026
Vishwas SetiaChief Financial Officer356,2560.77%May 6, 2026
Troy CoxDirector23,4840.05%Jul 28, 2026
George PavlovDirector28,9320.06%Jun 25, 2026
Martin BablerDirector7,8640.02%Jun 25, 2026
Maria C. WalkerDirector62,7030.14%Jun 25, 2026
Timothy John GarnettDirector67,5810.15%Jun 25, 2026
Nanna Liebach LuneborgDirector3,9320.01%Jun 25, 2026
Robert C. MalenkaDirector348,1380.75%Apr 17, 2026
James D. TrenkleDirector––Oct 27, 2025
Catalyst4, Inc.10% owner25,306,68954.57%Aug 18, 2026
Holdings A/S Novo10% owner2,733,6815.89%Oct 30, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Anatol Kreitzer
Chief Discovery Officer
Oct 15, 2026Sale−12,248$7.84$96.02K168,678
Erin Pennock Foff
Chief Medical Officer
Oct 15, 2026Sale−15,355$8.08$124.07K296,906
Kristopher Hanson
General Counsel
Oct 15, 2026Sale−9,020$8.08$72.88K128,024
James Woodruff Lillie
Chief Scientific Officer
Oct 15, 2026Sale−11,513$8.08$93.03K198,597
Jonathan Gillis
CAO and Interim CFO
Oct 15, 2026Sale−10,167$8.08$82.15K142,315
Christopher A. Kroeger
Chief Executive Officer, Director
Oct 15, 2026Sale−73,691$8.08$595.42K1,195,909
Kristopher Hanson
General Counsel
Sep 16, 2026Sale(10b5-1 plan)−16,509$11.67$192.66K137,044
Kristopher Hanson
General Counsel
Aug 17, 2026Award+7,730––153,553
Christopher A. Kroeger
Chief Executive Officer, Director
Aug 17, 2026Award+23,145––1,269,600
Erin Pennock Foff
Chief Medical Officer
Aug 17, 2026Award+13,360––312,261
James Woodruff Lillie
Chief Scientific Officer
Aug 17, 2026Award+7,730––210,110
Anatol Kreitzer
Chief Discovery Officer
Aug 17, 2026Award+6,020––180,926
Jonathan Gillis
CAO and Interim CFO
Aug 17, 2026Award+2,222––152,482
Jonathan Gillis
CAO and Interim CFO
Aug 17, 2026Award+6,020––150,260
Catalyst4, Inc.
10% owner
Aug 14, 2026Buy+4,400,000$11.38$50.07M25,306,689
James Woodruff Lillie
Chief Scientific Officer
Aug 3, 2026Sale(10b5-1 plan)−22,082$12.54$276.91K202,380
Catalyst4, Inc.
10% owner
Jul 30, 2026Buy+1,000,000$13.00$13.00M20,906,689
Catalyst4, Inc.
10% owner
Jul 29, 2026Buy+3,000$12.63$37.89K19,906,689
Catalyst4, Inc.
10% owner
Jul 28, 2026Buy+141,088$10.74$1.52M19,838,552
Catalyst4, Inc.
10% owner
Jul 28, 2026Buy+65,137$11.69$761.45K19,903,689
Troy Cox
Director
Jul 28, 2026Buy+15,620$9.52$148.70K15,620
Jonathan Gillis
CAO and Interim CFO
Jul 17, 2026Sale(10b5-1 plan)−900$38.17$34.35K144,240
Jonathan Gillis
CAO and Interim CFO
Jul 17, 2026Sale(10b5-1 plan)−600$36.51$21.91K162,109
Jonathan Gillis
CAO and Interim CFO
Jul 17, 2026Sale(10b5-1 plan)−16,969$37.61$638.20K145,140
Anatol Kreitzer
Chief Discovery Officer
Jul 17, 2026Sale(10b5-1 plan)−2,833$37.05$104.96K189,246
Anatol Kreitzer
Chief Discovery Officer
Jul 17, 2026Sale(10b5-1 plan)−14,140$37.70$533.08K175,106
Anatol Kreitzer
Chief Discovery Officer
Jul 17, 2026Sale(10b5-1 plan)−200$38.39$7.68K174,906
James Woodruff Lillie
Chief Scientific Officer
Jul 17, 2026Sale−2,077$37.90$78.72K224,462
Christopher A. Kroeger
Chief Executive Officer, Director
Jul 17, 2026Sale−16,779$37.90$635.92K1,246,455
Kristopher Hanson
General Counsel
Jul 17, 2026Sale−1,130$37.90$42.83K145,823
Erin Pennock Foff
Chief Medical Officer
Jul 17, 2026Sale(10b5-1 plan)−3,656$37.90$138.56K298,901
Jonathan Gillis
CAO and Interim CFO
Jul 16, 2026Sale(10b5-1 plan)−1,476$37.44$55.26K162,709
Jonathan Gillis
CAO and Interim CFO
Jul 16, 2026Sale(10b5-1 plan)−6,979$36.66$255.85K164,185
Anatol Kreitzer
Chief Discovery Officer
Jul 16, 2026Sale(10b5-1 plan)−7,464$36.66$273.63K193,671
Anatol Kreitzer
Chief Discovery Officer
Jul 16, 2026Sale(10b5-1 plan)−1,592$37.44$59.60K192,079
James Woodruff Lillie
Chief Scientific Officer
Jul 16, 2026Sale−5,009$36.45$182.58K230,077
James Woodruff Lillie
Chief Scientific Officer
Jul 16, 2026Sale−3,526$37.26$131.38K226,551
James Woodruff Lillie
Chief Scientific Officer
Jul 16, 2026Sale−12$37.96$456226,539
Christopher A. Kroeger
Chief Executive Officer, Director
Jul 16, 2026Sale−40,899$36.46$1.49M1,291,417
Christopher A. Kroeger
Chief Executive Officer, Director
Jul 16, 2026Sale−92$37.96$3.49K1,263,234
Christopher A. Kroeger
Chief Executive Officer, Director
Jul 16, 2026Sale−28,091$37.26$1.05M1,263,326
Kristopher Hanson
General Counsel
Jul 16, 2026Sale−11$37.96$418146,953
Kristopher Hanson
General Counsel
Jul 16, 2026Sale−4,776$36.45$174.09K150,295
Kristopher Hanson
General Counsel
Jul 16, 2026Sale−3,331$37.26$124.11K146,964
Erin Pennock Foff
Chief Medical Officer
Jul 16, 2026Sale(10b5-1 plan)−9,163$36.46$334.08K308,441
Erin Pennock Foff
Chief Medical Officer
Jul 16, 2026Sale(10b5-1 plan)−5,865$37.26$218.53K302,576
Erin Pennock Foff
Chief Medical Officer
Jul 16, 2026Sale(10b5-1 plan)−19$37.96$721302,557
Jonathan Gillis
CAO and Interim CFO
Jul 15, 2026Sale(10b5-1 plan)−4,699$36.94$173.58K171,164
Jonathan Gillis
CAO and Interim CFO
Jul 15, 2026Sale(10b5-1 plan)−5,356$36.13$193.51K175,863
Anatol Kreitzer
Chief Discovery Officer
Jul 15, 2026Sale(10b5-1 plan)−5,545$36.13$200.34K205,645
Anatol Kreitzer
Chief Discovery Officer
Jul 15, 2026Sale(10b5-1 plan)−4,510$36.94$166.60K201,135
James Woodruff Lillie
Chief Scientific Officer
Jul 15, 2026Sale−2,238$36.00$80.57K240,491
James Woodruff Lillie
Chief Scientific Officer
Jul 15, 2026Sale−12$37.54$450235,086
James Woodruff Lillie
Chief Scientific Officer
Jul 15, 2026Sale−5,393$36.99$199.49K235,098
Christopher A. Kroeger
Chief Executive Officer, Director
Jul 15, 2026Sale−90$37.54$3.38K1,332,316
Christopher A. Kroeger
Chief Executive Officer, Director
Jul 15, 2026Sale−42,738$36.99$1.58M1,332,406
Christopher A. Kroeger
Chief Executive Officer, Director
Jul 15, 2026Sale−18,950$36.00$682.20K1,375,144
Kristopher Hanson
General Counsel
Jul 15, 2026Sale−10$37.54$375155,071
Kristopher Hanson
General Counsel
Jul 15, 2026Sale−2,147$36.00$77.29K160,184
Kristopher Hanson
General Counsel
Jul 15, 2026Sale−5,103$36.99$188.76K155,081

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
7.01%
3M shares short
Days to cover
10.3
At 0M shares a day
Change since last report
-2.1%
From 3M shares
Short volume, 20 days
42.3%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of MapLight Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 3,752 shares on Sep 10, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Erin Pennock Foff
Officer
Oct 15, 202615,355$119.92KOct 15, 2026Restricted Stock Unit Grant
Christopher A. Kroeger
Officer
Oct 15, 202673,691$575.53KOct 15, 2026Restricted Stock Unit Grant
James Woodruff Lillie
Officer
Oct 15, 202611,513$89.92KOct 15, 2026Restricted Stock Unit Grant
Robert C. Malenka
Director
Oct 15, 202614,809$115.66KOct 15, 2026Restricted Stock Units
Anatol Kreitzer
Officer
Oct 15, 202612,500$97.63KOct 15, 2026Restricted stock unit settlement
Kristopher Hanson
Officer
Oct 15, 20269,020$70.45KOct 15, 2026Restricted Stock Unit Grant
Jonathan Gillis
Officer
Oct 15, 202610,167$79.40KOct 15, 2026Restricted Stock Unit Grant
Kristopher Hanson
Officer
Sep 16, 202616,509$199.43KSep 16, 2026Vested RSU
James Woodruff Lillie
Officer
Aug 3, 202622,082$287.51KAug 3, 2026Vested RSU
Holdings A/S Novo
Former Affiliate
Jul 30, 20261,600,000$24.03MJul 30, 2026Direct Investment
Anatol Kreitzer
Officer
Jul 17, 202617,173$639.18KJul 17, 2026Restricted Stock Units
Jonathan Gillis
Officer
Jul 17, 202618,469$687.42KJul 17, 2026Restricted Stock Units
Christopher A. Kroeger
Officer
Jul 15, 2026152,230$5.77MJul 15, 2026Restricted Stock Unit Grant
Robert C. Malenka
Director
Jul 15, 202617,537$664.83KJul 15, 2026Restricted Stock Units
Erin Pennock Foff
Officer
Jul 15, 202648,158$1.83MJul 15, 2026Restricted Stock Unit Grant

See a number that looks wrong?